Valneva Submits Delisting Application to the Vienna Stock Exchange
02 Juillet 2019 - 5:45PM
Valneva Submits Delisting
Application to the Vienna Stock Exchange
- Annual general meeting on June 27, 2019 resolved on the
delisting of Valneva’s ordinary shares from the Vienna Stock
Exchange
- Delisting shall be effective by the end of
2019
- Listing on Euronext Paris remains
unchanged
Saint Herblain (France), July 2,
2019 – Valneva SE (“Valneva” or “the Company”), a biotech
company developing and commercializing vaccines for infectious
diseases with major unmet needs, announces today that it has
submitted a request to revoke the admission of its shares to the
Vienna Stock Exchange (VSE). This decision was made by the Company
in order to focus on the best capital markets for life science
companies and increase liquidity by centralizing trading on
Euronext Paris.
The application was submitted to VSE after
Valneva’s annual general meeting, which resolved on the revocation
of the admission of the Company’s ordinary shares from the Official
Market (Amtlicher Handel) of the VSE, according to §38 (6) of the
Austrian Stock Exchange Act 2018.
The VSE will now have ten weeks to decide on the
application and timeline of the delisting. A period of at least
three months between the publication of VSE’s decision and the
effective date of the delisting is required, which potentially
places the effective delisting date by the end of 2019.
Valneva’s ordinary shares have been listed on
the VSE since May 28, 2013 and admitted to trade on the Official
Market (Amtlicher Handel) in the Prime Market (ISIN FR0004056851).
They are further listed on Euronext Paris (compartment B) where
they will continue to trade. Valneva’s preferred shares (ISIN
FR0011472943) are traded on the VSE’s Third Market Segment (MTF)
and on Euronext Paris.
The trading of the preferred shares in the Third
Market (MTF) on the Vienna Stock Exchange shall terminate in
parallel to the termination of trading of the ordinary shares on
the Vienna Stock Exchange.
The ordinary shares and the preferred shares
remain tradeable on the Euronext Paris, a regulated market within
the meaning of §1 (2) of the Austrian Stock Exchange Act 2018.
For further information please visit
www.valneva.com/en/vsedelisting or email the Investor
Relations department in Vienna at investors@valneva.com.
ISIN
FR0004056851 (ordinary shares), FR0011472943 (preferred shares)
Stock exchangesOfficial Market (Prime Market)
Vienna Stock Exchange; Compartment B Euronext Paris, France
About Valneva SE
Valneva is a biotech company developing and
commercializing vaccines for infectious diseases with major unmet
needs. Valneva’s portfolio includes two commercial vaccines for
travelers: IXIARO®/JESPECT® indicated for the prevention of
Japanese encephalitis and DUKORAL® indicated for the prevention of
cholera and, in some countries, prevention of diarrhea caused by
ETEC. The Company has various vaccines in development including a
unique vaccine against Lyme disease. Valneva has operations in
Austria, Sweden, the United Kingdom, France, Canada and the US with
approximately 480 employees. More information is available at
www.valneva.com.
Valneva
Investor and Media ContactsLaetitia
Bachelot-FontaineGlobal Head of Investor Relations & Corporate
CommunicationsM +33 (0)6 4516 7099investors@valneva.com |
Teresa
PinzolitsCorporate Communications SpecialistT +43 (0)1 20620
1116communications@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing and completion of
research, development and clinical trials for product candidates,
the ability to manufacture, market, commercialize and achieve
market acceptance for product candidates, the ability to protect
intellectual property and operate the business without infringing
on the intellectual property rights of others, estimates for future
performance and estimates regarding anticipated operating losses,
future revenues, capital requirements and needs for additional
financing. In addition, even if the actual results or development
of Valneva are consistent with the forward-looking statements
contained in this press release, those results or developments of
Valneva may not be indicative of their in the future. In some
cases, you can identify forward-looking statements by words such as
"could," "should," "may," "expects," "anticipates," "believes,"
"intends," "estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release, and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
- 2019_07_02_VSE_Delisting_Application_PR_EN